Literature DB >> 25668894

Piperacillin-induced DRESS: distinguishing features observed in a clinical and allergy study of 8 patients.

R Cabañas, O Calderon, E Ramirez, A Fiandor, N Prior, T Caballero, P Herránz, I Bobolea, M C López-Serrano, S Quirce, T Bellón.   

Abstract

BACKGROUND: DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome is characterized by fever, rash, eosinophilia, and multiorgan failure. Previous reports have described differences in clinical and laboratory findings of DRESS syndrome depending on the inducing drug. Piperacillin has been reported as the drug responsible for this syndrome in 3 patients.
OBJECTIVE: To analyze and describe the clinical, laboratory, and allergy study findings of piperacillin-induced DRESS. PATIENTS AND METHODS: Retrospective case series of patients diagnosed with DRESS associated with piperacillin-tazobactam (Pip/Taz) according to the Kardaun diagnostic score criteria. Assessment of causality was established using the Spanish Pharmacovigilance System and the lymphocyte transformation test (LTT). The allergy study included skin and epicutaneous tests.
RESULTS: Eight patients were diagnosed with DRESS due to Pip/Taz (3 probable and 5 definite cases). Skin rash was observed in all cases and facial edema in 50%; the mean latency period was 18 days. Fever was present in 7 patients. Liver and kidney injuries were detected in 6 and 3 patients, respectively. All patients had eosinophilia and a full recovery. The LTT to Pip/Taz was strongly positive in all patients, with a stimulation index of over 6. Three of 3 patients had a positive intradermal test to Pip/Taz, and 1 of 4 had a positive patch test. All patients had a negative LTT to carbapenems.
CONCLUSIONS: We have reported on the first case series of piperacillin-induced DRESS. A latency period of 18 days, skin rash, eosinophilia, fever, liver injury, and good prognosis were the most common features. The allergy study, and the LTT in particular, was highly useful for identifying Pip/Taz as the culprit drug and piperacillin as the responsible active ingredient.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25668894

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  14 in total

1.  The safety of antibiotic skin testing in severe T-cell-mediated hypersensitivity of immunocompetent and immunocompromised hosts.

Authors:  Jason A Trubiano; Abby P Douglas; Michelle Goh; Monica A Slavin; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2018-09-26

Review 2.  The 3 Cs of Antibiotic Allergy-Classification, Cross-Reactivity, and Collaboration.

Authors:  Jason A Trubiano; Cosby A Stone; M Lindsay Grayson; Karen Urbancic; Monica A Slavin; Karin A Thursky; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2017-08-23

Review 3.  Recent advances in the understanding of severe cutaneous adverse reactions.

Authors:  N R Adler; A K Aung; E N Ergen; J Trubiano; M S Y Goh; E J Phillips
Journal:  Br J Dermatol       Date:  2017-09-29       Impact factor: 9.302

4.  The Combined Utility of Ex Vivo IFN-γ Release Enzyme-Linked ImmunoSpot Assay and In Vivo Skin Testing in Patients with Antibiotic-Associated Severe Cutaneous Adverse Reactions.

Authors:  Jason A Trubiano; Kaija Strautins; Alec J Redwood; Rebecca Pavlos; Katherine C Konvinse; Ar Kar Aung; Monica A Slavin; Karin A Thursky; M Lindsay Grayson; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2017-10-31

Review 5.  Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity.

Authors:  Katherine C Konvinse; Elizabeth J Phillips; Katie D White; Jason A Trubiano
Journal:  Curr Opin Infect Dis       Date:  2016-12       Impact factor: 4.915

6.  Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go?

Authors:  Rannakoe J Lehloenya; Jonny G Peter; Ana Copascu; Jason A Trubiano; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2020-10

7.  DRESS Syndrome in the ICU: When a Patient Is Treated with Multiple Drugs.

Authors:  Florent Moriceau; Johanne Prothet; Benjamin J Blaise; Benoit Ben Said; Mathieu Page; Charles-Eric Ber; Jullien Crozon; Thomas Rimmelé
Journal:  Case Rep Crit Care       Date:  2016-01-24

8.  In Vitro Assays in Severe Cutaneous Adverse Drug Reactions: Are They Still Research Tools or Diagnostic Tests Already?

Authors:  Grzegorz Porebski
Journal:  Int J Mol Sci       Date:  2017-08-10       Impact factor: 5.923

Review 9.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System.

Authors:  Yung-Tsu Cho; Che-Wen Yang; Chia-Yu Chu
Journal:  Int J Mol Sci       Date:  2017-06-09       Impact factor: 5.923

Review 10.  Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review.

Authors:  Shiva Sharifzadeh; Amir Hooshang Mohammadpour; Ashraf Tavanaee; Sepideh Elyasi
Journal:  Eur J Clin Pharmacol       Date:  2020-10-06       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.